Home » Stocks » PHAR » Company

Pharming Group N.V. (PHAR)

Stock Price: $11.42 USD 0.25 (2.24%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Pharming Group N.V.
Country Netherlands
Founded 1988
Industry Research and Development in Biotechnology
Sector Professional, Scientific, and Technical Services
Employees 262
CEO Sijmen de Vries

Contact Details

Address:Darwinweg 24
Leiden, Zuid Holland 2333 CR
Phone 31715247400

Stock Information

Ticker Symbol PHAR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 1828316
CUSIP Number 71713J107

Company Description

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.

The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases.

The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Key Executives

Sijmen de Vries, MD MBAChief Executive Officer
Jeroen WakkermanChief Financial Officer
Bruno M.L. Giannetti, MD PhDChief Medical Officer
Anne-Marie de GrootSenior Vice President, Organizational Development
Mireille Sanders, MScSenior Vice President, Operations
Stephen ToorSenior Vice President and General Manager Pharming America
Paul SekhriChairperson
Chairperson Deborah Jorn, MBAVice Chairperson